What are the adverse drug reactions associated with febuxostat?

Adverse Drug Reactions of Febuxostat

The most critical adverse drug reaction of febuxostat is increased cardiovascular mortality, particularly cardiovascular death, which led to an FDA black box warning and should prompt consideration of switching to alternative urate-lowering therapy in patients with pre-existing cardiovascular disease. 1

Cardiovascular Adverse Events (Most Serious)

Cardiovascular mortality and events represent the most concerning safety signal with febuxostat:

• Increased cardiovascular death and all-cause mortality compared to allopurinol was demonstrated in the FDA-mandated CARES trial, though the primary composite cardiovascular endpoint showed no difference 1
• The American College of Rheumatology conditionally recommends switching to an alternative urate-lowering agent for patients taking febuxostat with a history of cardiovascular disease or new cardiovascular events 1
• Specific cardiovascular risks include: heart failure, ischemic heart disease, hypertension, and cardiomyopathy, particularly in elderly gout patients 2
• Asian population studies show increased risk of acute coronary syndrome (HR 1.06), atrial fibrillation (HR 1.19), acute decompensated heart failure, and cardiovascular death compared to allopurinol 3
• The cardiovascular risk appears highest when febuxostat is combined with acetic acid derivative NSAIDs 2

Important caveat: The CARES trial had a high dropout rate with most deaths occurring after discontinuation, and observational studies show conflicting results, with some showing no increased cardiovascular risk 1

Common Non-Cardiovascular Adverse Reactions

Gastrointestinal and musculoskeletal effects are the most frequently reported:

• Abdominal pain, diarrhea are among the most common adverse events 1
• Musculoskeletal pain and joint-related symptoms occur frequently 1, 4
• Headache and arthralgias are commonly reported 4

Hepatic Adverse Reactions

• Abnormal liver function tests are among the most common adverse reactions, requiring monitoring 4
• The clinical significance of these abnormalities warrants further investigation 4

Cutaneous Adverse Reactions

Febuxostat has significantly lower risk of skin reactions compared to allopurinol:

• Skin rash occurs but is substantially less common than with allopurinol (adjusted IRR 0.55) 5
• Severe cutaneous adverse reactions are rare but have been reported post-marketing, including fatal cases 5
• Febuxostat shows lower rates of mild, severe, and fatal cutaneous adverse reactions compared to allopurinol (IRR 1.86,16.75, and 16.18 respectively for allopurinol vs febuxostat) 5
• Close monitoring during initiation is still warranted despite lower overall risk 5

Hematologic Adverse Reactions (Rare but Serious)

• Agranulocytosis has been reported, particularly in patients with end-stage renal disease 6
• This is a rare but potentially life-threatening adverse effect requiring immediate discontinuation and close hemogram monitoring 6

Gout Flare Provocation

Paradoxical gout flares are common during initiation:

• Up to 70% of patients experience gout flares during at least the first year of therapy despite prophylactic colchicine or naproxen 4
• Higher doses of febuxostat (120-240 mg/day) are associated with higher flare incidence compared to allopurinol 1
• Prophylactic therapy with colchicine or NSAIDs is recommended when initiating febuxostat 1

Population-Specific Considerations

Patients with cardiovascular disease require special attention:

• The FDA black box warning specifically addresses cardiovascular risk 1
• Shared decision-making is essential when considering febuxostat in patients at high cardiovascular risk 1
• Peripheral edema and peripheral swelling are the most frequently reported cardiovascular adverse events (14.38% and 8.76% respectively) 2

Patients with severe renal impairment:

• Insufficient safety data exists for patients with severe renal impairment and end-stage renal disease 6
• Agranulocytosis risk may be elevated in this population 6